Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation

@inproceedings{Isobe2014ClinicalSO,
  title={Clinical Significance of BIM Deletion Polymorphism in Non–Small-Cell Lung Cancer with Epidermal Growth Factor Receptor Mutation},
  author={Kazutoshi Isobe and Yoshinobu Hata and Naobumi Tochigi and Kyohei Kaburaki and Hiroshi Kobayashi and Takashi Makino and Hajime Otsuka and Fumitomo Sato and Fumiaki Ishida and Naoshi Kikuchi and Nao Hirota and Keita Sato and G O Sano and Keishi Sugino and Susumu Sakamoto and Yujiro Takai and Kazutoshi Shibuya and Akira Iyoda and Sakae Homma},
  booktitle={Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer},
  year={2014}
}
BACKGROUND Germline alterations in the proapoptotic protein Bcl-2-like 11 (BIM) can have a crucial role in tumor response to treatment. To determine the clinical utility of detecting BIM deletion polymorphism in non-small-cell lung cancer positive for epidermal growth factor receptor (EGFR) mutation, we examined outcomes of patients with and without BIM alterations. METHODS We studied 70 patients with EGFR mutation-positive non-small-cell lung cancer who were treated with an EGFR tyrosine… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 4 times. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 23 extracted citations

Primary Double-Strike Therapy for Cancers to Overcome EGFR Kinase Inhibitor Resistance: Proposal from the Bench.

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer • 2017

References

Publications referenced by this paper.
Showing 1-10 of 26 references

Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2013

Similar Papers

Loading similar papers…